Harvard Medical School's Dr. Scott Shikora presents data from EnteroMedics ' ( ETRM +5.1% ) 28-patient DM2 ENABLE study assessing the feasibility of VBLOC vagal block therapy delivered via its Maestro RC System
Gainers: SGOC +30.4% . DGLY +21.67% . CREG +20.14% . RPRX +16.42% . ETRM +13.87% . LAS +13.23% . SCOK +10.71% . COBR +9.57% . TKMR +8.61% . SIG +5.65% . Losers: GOMO -20.19
By Life Sciences Report : Rapid growth in the medical device industry and changes in the regulatory environment have propelled valuations in the medtech sector to the high end of the range. But new technologies create new investment opportunities. In this interview with The Life Sciences Report ,
June 18 (Reuters) - EnteroMedics Inc's shares jumped about 37 percent in premarket trading on Wednesday, a day after an advisory panel to the U.S. Food and Drug Administration voted in favor of the...
We are no longer providing equity research on EnteroMedics ETRM . We provide broad coverage of more than 1,700 companies across more than 140 industries and adjust our coverage as necessary based on client demand and investor interest.
EnteroMedics ETRM posted third-quarter results that ..... value estimate unchanged. Although EnteroMedics has begun to roll out its Maestro system ..... until after 2017. In the meantime, EnteroMedics burned through another $5.6 million
EntroMedics ETRM has made significant progress ..... valuation shortly. Now that EnteroMedics has shored up its cash ..... full year 2012. While EnteroMedics began its launch in Kuwait ..... 2013, especially after EnteroMedics has submitted its last
Now that EnteroMedics ETRM has made significant progress on ..... Australia. For the first time, EnteroMedics booked product revenue, following ..... distributor. Perhaps most important, EnteroMedics has put financing in place to keep
EnteroMedics ETRM saw its shares run up substantially ..... outcome has breathed some hope into EnteroMedics ' stock. However, this is not enough ..... to raise our fair value estimate for EnteroMedics at this time. Nonetheless, we are
EnteroMedics ETRM shared favorable data on its obesity ..... fourth quarter, which is when we expect EnteroMedics will run out of cash. We're not ..... what happened several years ago, when EnteroMedics reported impressive weight loss results